With the merger, Processa’s new lead asset is a Vidya Therapeutics immunology drug that offers pipeline-in-a-product potential addressing a target that has clinical and regulatory validation from a recently approved Novartis drug. Vidya’s molecule is a next-generation drug that could have advantages over Novartis’s pill.
The post Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product appeared first on MedCity News.
